Compare · ABEO vs NVO
ABEO vs NVO
Side-by-side comparison of Abeona Therapeutics Inc. (ABEO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABEO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $204.85B, about 625.1x ABEO ($327.7M).
- Over the past year, ABEO is down 1.4% and NVO is down 32.0% - ABEO leads by 30.6 points.
- ABEO has been more active in the news (11 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 7 for ABEO).
- Company
- Abeona Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $5.74+0.00%
- $47.40+3.29%
- Market cap
- $327.7M
- $204.85B
- 1M return
- +3.80%
- +6.83%
- 1Y return
- -1.37%
- -32.01%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 11
- 3
- Recent ratings
- 7
- 25
Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ABEO
- Chief Commercial Officer Vasanthavada Madhav disposed of $1,259 worth of shares (222 units at $5.67), decreasing direct ownership by 0.07% to 303,229 units (SEC Form 4) (withholding tax)
- Director Silverstein Christine Berni sold $103,695 worth of shares (18,160 units at $5.71), decreasing direct ownership by 13% to 119,562 units (SEC Form 4) to satisfy tax liability
- Abeona Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Abeona Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Abeona Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Chief Commercial Officer Vasanthavada Madhav sold $51,549 worth of shares (9,620 units at $5.36), decreasing direct ownership by 3% to 303,451 units (SEC Form 4) to satisfy withholding obligation
- SVP, Chief Legal Officer O'Malley Brendan M. sold $59,646 worth of shares (11,131 units at $5.36), decreasing direct ownership by 2% to 440,003 units (SEC Form 4) to satisfy withholding obligation
- Chief Financial Officer Vazzano Joseph Walter sold $265,242 worth of shares (49,338 units at $5.38) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 518,437 units (SEC Form 4) to cover taxes
- Chief Executive Officer Seshadri Vishwas sold $301,921 worth of shares (56,344 units at $5.36), decreasing direct ownership by 4% to 1,374,079 units (SEC Form 4) (for withholding tax)
- Abeona Therapeutics Inc. filed SEC Form 8-K: Other Events
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S